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Abstract: To prevent the high frequency of wound infec-
tions, anti-bacterial agents can be loaded onto compos-
ites. In the present study, the antibiotic tetracycline hy-5
drochloride (TC)was incorporated, for the first time, in col-
lagen type Imembranes coatedwith nano-sized SiO2-CaO-
P2O5 bioactive glass (n-BG) obtained by a sol-gel chemical
route.
Collagen membranes coated with n-BG were immersed10
in simulated body fluid (SBF) containing 0.25, 0.75 or
1.25 mg mL−1 of TC for 48 h at 37∘C following a co-
precipitation method. The antibiotic was released in dis-
tilled water at 37∘C for up to 72 h. The antibacterial activity
of the composites was evaluated in vitro by the inhibition15
zone test and plate count method. Two different Staphylo-
coccus aureus strains, S. aureus ATCC29213 and S. aureus
ATCC25923, were exposed to the biomaterials. The results
showed that the incorporation but not the release of TC
was dependent on the initial concentration of TC in SBF.20
The biomaterials inhibited S. aureus growth, although the
efficacy was similar for all the concentrations. The results
allow us to conclude that the new composite could have
potential in the prevention of wound infections.
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1 Introduction
Antibiotic release systems such as polymeric matrices
have become some of themost promising strategies for the
prophylaxis and management of different kinds of wound 30
infections (i.e. burns, pressure ulcers, post-surgical ul-
cers) [1–8]. However, the in vivo degradation process by
proteases makes polymeric matrices prone to rapidly re-
lease the encapsulated drug, thus preventing long-term
maintenance of therapeutic levels [9]. One alternative way 35
to modulate antibiotic release over an extended period of
time is through covalent binding of the drug so that sus-
tained release may be maintained by the rate of biodegra-
dation. Some authors have explored this possibility by fol-
lowing the co-precipitation process [10, 11]. 40
Bioactive glasses (BGs) have started to be considered
as carriers for different drugs [12] because they have been
shown to be biocompatible and bioresorbable with a con-
trollable degradation and resorption process [13]. Com-
pared with micro-sized BGs, nano-sized BGs (n-BGs) have 45
many advantages when polymeric-bioceramic composites
are synthesized. Theuse of n-BGs on apolymericmatrix al-
lows a more homogeneous distribution of particles within
thepolymericmatrix andmanymoreparticles for the same
equivalent weight of carriers. In addition, it allows an en- 50
hanced performance of the mechanical properties of com-
posites and enhanced [14].
In the frame of soft tissue regeneration, it has been
shown that n-BGs prepared using the sol-gelmethod could
promote the stiffness and elongation of endothelial cells 55
and the formation of endothelial networks in vitro [15].
Therefore,wehypothesized that such inorganic biomateri-
als could facilitate the vascularization in vivo, which could
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be relevant for the envisaged application of the devices
developed in this work. Histological examination showed
that n-BG can accelerate the recovery of skin wounds in
both normal and diabetes-impaired healing models [16].
Tetracycline hydrochloride (TC) is a broad-spectrum5
antibiotic that inhibits protein synthesis [17]. TC is also
considered an option to treat problems of skin and soft
tissue infections (SSTIs) caused by methicillin-resistant
Staphylococcus aureus (MRSA) [18, 19] and even consid-
ered the most efficacious and cost-effective oral treatment10
for MRSA [20].
This is relevant considering that the most common
pathogens that cause SSTIs are streptococci and S. au-
reus [6, 21]. In vivo results show that TC coupled to BGs has
no additional irritant effect that could prevent its usage in15
association with BGs [22].
On the other hand, it has been convincingly demon-
strated that TC binds to synthetic crystals of apatite, es-
pecially during their formation in vitro [23, 24]. This im-
plies that the antibiotic can co-precipitate with calcium on20
a polymeric matrix during the bioactivity process of BG in-
cubated in simulated body fluid (SBF).
Many researchers have encapsulated TC into BGs pre-
pared by the sol-gel method during their synthesis at
room temperature [22, 25–27]. Nevertheless, biodegrad-25
able polymers plus n-BG as matrix for the release of TC
have been poorly explored. Also, antibacterial effects are
sometimes overlooked.
On the other hand, it has been shown that the
TC release behavior changes as the BG composition30
changes [28].
We have previously studied the incorporation, TC re-
lease and antibacterial effects of collagen type I compos-
ites coated with 45S5 n-BG [29]. In this work, we incorpo-
rated three different initial concentrations of TC (0.25, 0.7535
and 1.5 mg mL−1) onto commercial type I collagen mem-
branes coated with nano-sized SiO2CaOP2O5 BG, quanti-
fied the incorporation and TC release, and investigated its
antibacterial effects on S. aureus ATCC29213 and S. aureus
ATCC25923.40
2 Methods
2.1 Materials
Bioactive glass nanoparticles (n-BG, 20–30 nm) with the
formulation SiO2:CaO:P2O5 (mol.%) = 55:40:5 were devel-
oped by sol-gel deposition [30]. Type I collagen bovine45
membranes (100 µm thick) were supplied by Laborato-
rio Celina (Buenos Aires, Argentina). TC in powder form
(Sigma-Aldrich) was used. Hank’s balanced saline solu-
tion (HBSS) without Ca2+ and Mg+ was obtained from Life
Technologies (Carlsbad, CA, USA). 50
2.2 Preparation of composites
A total of 100 mg of n-BG was used to coat type I collagen
bovine membranes (9 × 9 cm2). Each time, 10 mg of n-BG
was sonicated for 5 minutes in 20 mL of isopropanol and
then aliquots of 3 mL were used to coat the membranes 55
and left to dry in air at room temperature. At the end of the
process, the samples obtainedwere 3 × 3 cm2. The samples
were sterilized by Gamma-irradiation. Gamma-irradiation
sterilization was achieved at a dose of 2.5 Mrad 60Co at
room temperature. 60
2.3 Surface analysis of the samples
The materials obtained were morphologically character-
ized by scanning electron microscopy (SEM). To this end,
biomaterials were fixed with a 2.5% glutaraldehyde 0.1 M
phosphate buffered saline (PBS) solution overnight at 4∘C. 65
The sampleswere thenwashedwith distilledwater and se-
quentially dehydrated through a graded series of ethanol
solutions. After mounting on stubs and gold sputtering,
the samples were examined by SEM (JSM 6480 LV, JEOL
Ltd, Tokyo, Japan). 70
2.4 TC incorporation
First, a calibration curve was performed by measuring
UV absorbance of TC solutions ranging from 0.01 to
0.1 mg mL−1 at 350 nm (UV-Vis, Varian 500SCAN) [24].
TC was then incorporated at 37∘C in SBF, which was pre- 75
pared following Kokubo’s protocol [31]. The initial antibi-
otic concentrations were 0.25, 0.75 and 1.50mgmL−1. Each
n-BG-coatedmembranewas incubated for 48 h in 25mL of
SBF supplementedwith the above concentrations of TC. In
that way, the antibiotic co-precipitated and bound to n-BG 80
particles. The absorbance of aliquots of the TC-SBF solu-
tion was measured at different times. The initial volume
of the solution was maintained by replacing the amount
extracted from a solution made at the start of the exper-
iments and maintained in similar conditions. At the end 85
of the uptake, the samples, from now on TC-composites,
were washed in distilled water and allowed to dry at 25∘C.
The concentrations of TC incorporated were calculated by
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Figure 1: SEM images. Uncoated type I collagen membrane a) glass-
coated collagen membrane exposed to simulated body fluid (SBF)
for 48 h b). The bars represent 5 µm.
subtracting the remaining TC concentration at the differ-
ent timepoints from the initial concentration of the immer-
sion solutions.
The composites obtained using the above coating pro-
cesswere named as: CTC-025, CTC-075 andCTC-150 respec-5
tively, according to the initial concentration of TC in SBF.
2.5 Release of TC
TC release was evaluated in distilled water. TC-composites
were soaked in 25 mL of distilled water at 37∘C in static
conditions for 72 h. TC release was calculated by measur-10
ing the UV absorbance of 4 mL extracted at regular time
intervals, which was then placed back into the solution.
Tests were performed in triplicate, calculating the means
and standard deviations (SD).
2.6 Bacterial culture and preparation of15
inoculum
The following strains were used in this study: S. aureus
ATCC29213 and S. aureus ATCC25923. Both strains were
grown in Mueller Hinton broth (Britania S.A., Argentina)
at 37∘C for 24 h. For the experiments, bacterial cell suspen-20
sions were adjusted to 6–7 log cfu mL−1.
2.7 Antibacterial eflcacy
The performance of samples was evaluated by the inhibi-
tion zone test and the plate count method. For the inhi-
bition zone test, 100 µL of the described suspension was25
seeded on Mueller-Hinton agar plates on which samples
were then placed with the coated and treated surface in
contact with the plate. TC unloaded samples were used as
controls.
After 24 h incubation, inhibition zones were observed 30
as a halo around samples where bacteria had not grown.
The area of the inhibition zones was measured in mm. All
tests were performed in duplicate and the means and SD
were calculated.
For the plate count method, bacterial cell suspen- 35
sions were diluted to about 6 log cfu mL−1.The experi-
ments were carried out in HBSS without Ca2+ and Mg+.
The TC-composite samples were incubated for 48 h at 37∘C
in 25 mL of cell suspensions. Staphylococcus suspensions
in the absence of biomaterial served as controls. Samples 40
were collected after 24 and 48 h of incubation and the via-
bility of cells at 37∘C was assessed by counting in Mueller-
Hinton agar plates. After incubation, composites were pre-
pared for SEMobservation. The results are expressedas log
cfumL−1 ±SD.All testswereperformed in triplicate and the 45
means and SD were calculated.
2.8 Statistical analysis
Statistical analysis was performed using the SPSS 15.0
statistical package software with appropriate statistical
tests such as one-way analysis of variance (ANOVA) with 50
Tukey’s multiple comparison post-tests for inter-group
analysis. The level of significance was set at a p value of
< 0.05.
3 Results and Discussion
In this work, TC was incorporated onto collagen mem- 55
branes coated with nano-sized SiO2-CaO-P2O5 BG, follow-
ing a co-precipitationmethod. Compositeswere incubated
in SBF with different TC concentrations to promote the
drugdeposition considering the ability of TC to chelate cal-
cium. This kind of methodology for antibiotic deposition 60
has been previously reported elsewhere [10, 11, 32].
Figure 1 shows SEMmicrographs of the surfaces of an
uncoated type I collagenmembrane (a) and a glass-coated
collagenmembrane exposed to SBF containing TC for 48 h
(b). The collagen membrane presents randomly arranged 65
collagen fibrils forming a dense fibrous network. The pres-
ence of n-BG plus TC introduced a continuous coatingwith
pits and irregularities. This kind of morphology may influ-
ence the release behavior of the drug, as we will discuss
later. 70
The TC uptake values for TC-composites are presented
in Figure 2. The assay was performed for 3, 12, 24 and
48 h. Themajority of TC incorporation occurred within the
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Table 1: Summary of the incorporation and release behavior of tetracycline hydrochloride (TC).
Initial concentration % incorporation Incorporation % release Release
(mg mL−1) at 48 h at 48 h (mg cm2) at 72 h at 72 h (µg cm2)
0.25 49.99 ± 2.96 0.38 ± 0.02 14.41 ± 2.00 56.07 ± 1.52
0.75 45.69 ± 8.00 0.94 ± 0.16 5.30 ± 0.50 50.10 ± 4.77
1.50 41.94 ± 6.40 1.83 ± 0.63 2.90 ± 0.98 53.14 ± 3.65Figure 2 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Drug incorporation eflciencies as a function of time of
composites in TC solutions with different TC concentrations. The
data are expressed as the mean ± standard deviation; n = 3.
Figure 3 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: TC release profile from composites as a function of time,
with initial TC concentrations of 0.25, 0.75, and 1.50 mg mL−1. The
data are expressed as the mean ± standard deviation.
first 12 h. At this time, the percentage incorporation de-
creased as the TC concentration in SBF increased. How-
ever, at 48 h, the percentages of incorporationwere similar
for the three conditions (already 50%). These results con-
trast with our previous research work using 45S5 bioglass 5
nanoparticles, where the highest concentration of TC used
(0.035 mg mL−1) led to a higher percentage of TC deposi-
tion in collagen membranes [29]. Nevertheless, the extent
of incorporation in absolute terms was dependent on the
initial concentration of the drug. Therefore, while CTC-1.5 10
incorporated the highest absolute amount of TC, the per-
centage of incorporation was similar. This behavior is in
accordance both with our previous findings [29] and with
those of other authors [10, 24, 32].
Figure 3 shows the TC release behavior from the TC- 15
composites as a function of time up to 72 h of incubation.
The release behavior, defined by an initial rapid release
rate within the first 6 h followed by a stage of zero order
release (constant release rate) that lasted until the end of
the experiment, was similar for all composites. The release 20
percentage was inversely related to the initial TC concen-
tration because a greater percentage of TC release was ob-
served for CTC-025. However, the amount of TC released
was similar for the three conditions. Table 1 summarizes
the adsorption and release behavior of TC-composites. 25
The theoretical analysis and models of drug release
used to describe the release from polymers can also be ap-
plied for bioceramics [33]. The burst effects were typical
of diffusion controlled systems and observed for other re-
lated systems releasing TC [22, 25, 26, 28]. The constant 30
release rate presumably involved degradation of the pro-
teinmatrix combinedwith diffusion of the remaining drug
that was more firmly attached to the n-BG [34]. When the
percentage of cumulative release tends to decrease, like
in the case of CTC-025, a phenomenon of re-adsorption 35
takes place. This has been reported previously by other au-
thors [11, 24] and is due to the binding of calcium ions and
the TC released, which promotes the re-precipitation on
collagen membranes. We have previously observed a sim-
ilar phenomenon [29]. 40
Figure 4 summarizes the model of drug incorporation
proposed. Chemical incorporation occurred probably due
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Figure 4: Proposed scheme of different types of TC incorporated on
composites during incubation on SBF solution.
Figure 5 
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Figure 5: Inhibition zones around composites. S. aureus ATCC25923
(a), S. aureus ATCC29213 (b).
to the chelation of calcium ions [35, 36]. In line with pre-
vious findings [24], chemical incorporation is also con-
firmed by the change in color of membranes from yellow
to brown, which may have been due to the gradual pho-
todegradation of TC. The chelation between TC and cal-5
cium in SBF solution, observed as a precipitate, may com-
pete with the chelation between TC and calcium in the
membrane. These kinds of interactions increase with drug
concentration in the loading solution and interferewith TC
deposition and finally influence the release behavior [37].10
The greater percentage of TC released when the sam-
ples were incubated with the lowest TC concentration
(CTC-025) is in agreement both with other works [38] and
our previous results [29]. It has been proposed that when a
scaffold is immersed in a dilute drug solution, fewer drug15
molecules will enter the pores, and hence, the pore chan-
nels of the scaffoldswill contain fewerdrugmolecules [38].
A low drug entrapment will also result in the formation of
thinner films at the scaffold-dissolution medium interface
according to basic mass transfer phenomena. These con-20
ditions probably result in the reduced resistance to the dif-
fusion of drugmolecules, which favour faster drug release.
In other words, a decrease in the concentration of the drug
in the loading solution lowered the drug entrapment in the
scaffold. Although we did not work with an n-BG scaffold,25
the coated process on collagen membranes created mor-
phological irregularities in the composite surfaces, includ-
ing pores. In that sense, a similar phenomenon could ex-
plain the results obtained in this work.
A clear difference with our previous work using 45S5 30
n-BG can be highlighted. Although the TC initial concen-
trations were not the same, the initial drug concentration
of 0.25mgmL−1 can be used to compare the results of both
works. Sowewill discuss the result of this concentration in
the frame of comparison with the previous research work. 35
The concentrations of TC incorporated per cm2 were simi-
lar but the release timesweredifferent. The rapid release of
TC resulted in a shorter time in thiswork than that found in
our previous research. A possible explanation is that sol-
gel glasses tend to have an inherent nanoporosity [39] that 40
increases their specific surface area [40]. In the view that
the kinetics of antibiotic release are initially controlled to
some extent by surface phenomena [41], a larger area in-
crease the area for release and could explain the discrep-
ancies found. If this is right, it can be concluded that ad- 45
justing the BG system, the initial release rate can be con-
trolled.
The disc diffusion test is a good representation of the
clinical situation, where the dressing material is applied
to the wound surface, allowing the drug to diffuse to the 50
wound bed [9]. The results show clear inhibition zones
extending well beyond the composite margins (Fig. 5a,b).
The inhibition zone around the samples was similar for
the three TC-composites. This was expected because the
amount of TC released was also similar for the three TC- 55
composites. A similar strength was observed for both S.
aureus ATCC29213 and S. aureus ATCC25923. This is in ac-
cordance with our previous results [29]. For the different
TC-composites, the diameter of inhibition obtained was
50 ± 2 mm. 60
Viable bacteria counts provide valuable information
on the kill rate, which is a key comparator for different
formulations and physicochemical conditions [9]. The re-
sults of the viable counts are shown in Figure 6. Cell vi-
ability was significantly inhibited (p < 0.05) on the two S. 65
aureus strains in comparison to the control after 48 h of in-
cubation. The inhibitionwasnot found to bedependent on
TC concentration, as no statistically relevant differences
were found between the samples exposed to the different
concentrations of TC. In addition, no large differences in 70
inhibition strength were observed between the S. aureus
strains after 24 or 48 h of incubation. In accordance with
the zone inhibition test, the reduction in cell growth was
neither time- nor dose-dependent.
Drug delivery systems follow two distinct strategies, 75
according to the two different targets: treatment or prophy-
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Figure 6: Viable counts of S. aureus ATCC25923 (a) and S. aureus
ATCC29213 (b) in the presence of TC-composites.Figure 7 
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Figure 7: Interaction between Staphylococcus cells and the different
surfaces of the composites: uncoated collagen face (a), n-BG-coated
face (b).
laxis [42]. Many authors have defined that an infection is
established when the concentration of micro-organisms is
close to or exceeds 105 cells per gram of tissue or due to
the presence of beta-hemolytic streptococci [43, 44]. The
results found in this work show that the TC-composites5
are able to inhibit cell concentration up to 105 cfu mL−1
but failed to establish a cell concentration lower that
105 cfu mL−1 that would promote wound healing.
Similar antibacterial performance was found in our
previous work [29]. In that way, it seems that changing the10
BG system or the TC concentration does not reflect any im-
provement in terms of antibacterial effects.
The design of a drug delivery system for prophylaxis
includes, among other characteristics, a broad spectrum
antibiotic and concentration of antibiotic well above MICs15
that last for at least a few days/a week [42]. The clinical
MIC breakpoint for Staphylococcus spp. is ≤ 1mgL−1 (www.
eucast.org). Despite the low percentage of TC released, the
drug levels achieved in this study exceeded theMIC values
by several fold.20
Besidesmaterials eluting antimicrobials, the develop-
ment of anti-adhesivematerials against bacteria is another
strong strategy to prevent infections [45]. With less bac-
terial adhesion, the risk of biofilm formation could be re-
duced or delayed. Figure 7 shows the SEM images of the 25
presence of bacteria on the two surfaces of composites
(coated and uncoated). Much fewer bacterial cells were
present on the surface coated with n-BG, which was also
the surface exposed to the TC solutions (Fig. 7). These re-
sults also corroborate the antibacterial properties of TC- 30
composites. Reduced presence of bacteria has also been
observed on agar-gelatin films coated with 45S5 BG [46]
and on other polymers containing BG [47, 48]. Possible
explanations have been discussed in previous research
work [49] and include the repulsion that can occur be- 35
tween the bacterial cells and the BG surfaces and surface
phenomena.
4 Conclusions
This research work confirms the possibility to effectively
incorporate TC on type I collagen membranes coated with 40
nanoparticles of a ternary system of BG (SiO2CaOP2O5).
However, the technique also showed some limitations
sincewe found that a higher concentration not necessarily
leads to greater drug release or better antibacterial perfor-
mance. In future works, a further optimization of the ini- 45
tial drug concentration should be foreseen. TC-composites
showed a sustained release of TC over time and the kinet-
ics of the release achieved the requirements of a biomate-
rial eluting antibiotic for prophylaxis of wound infections,
i.e. a first fast releasing step to prevent the risk of infec- 50
tion followed by a sustained one. The amount of TC re-
leased by TC-composite samples was several-fold higher
than the MICs required for TC for the S. aureus strains
evaluated. This was confirmed by the inhibition zone test
and plate count method. Because of these reasons, the TC- 55
composites havepotential for theprophylaxis ofwound in-
fection.
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